Brief: Valbiotis Announces Positive Results From Its Phase I/II Clinical Study On LpD64

Valbiotis SA

11/09/2018 16:45

Sept 11 (Reuters) - VALBIOTIS SAS  ALVAL.PA :
    * VALBIOTIS ANNOUNCES POSITIVE RESULTS FROM ITS PHASE I/II
CLINICAL STUDY CONDUCTED ON LPD64 FOR OBESE SUBJECTS
    * VALIDATION OF TOLERABILITY AND SAFETY
    * COMPREHENSIVE SET OF RESULTS WILL BE PRESENTED AT THE
INTERNATIONAL DIABETES FEDERATION CONGRESS IN KUALA LUMPUR
(MALAYSIA) ON NOVEMBER 22, 2018
    * SUBSTANTIAL IMPROVEMENT OF OVER 33% ON INSULIN SENSITIVITY
COMBINED WITH AN IMPROVEMENT IN LIPID PROFILE
    * RESULTS SHOWED A SIGNIFICANT EFFECT ON ENERGY METABOLISM
IN
OBESE SUBJECTS
    * STUDY PAVES THE WAY FOR THE LAUNCH OF A PHASE II STUDY, TO
BE
CONDUCTED ON OVERWEIGHT AND OBESE SUBJECTS.

Source text for Eikon:  urn:newsml:reuters.com:*:nBw5J4wv6a
Further company coverage:  ALVAL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))